dr. (Hedwig) H.M. Blommestein

All publications (25)

• Article (23)

  • H.M. Blommestein, C.H.Y. van Beurden-Tan, M.G. Franken, C.A. de Uyl-de Groot, P. Sonneveld & S. Zweegman (2019). Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation - A network meta-analysis. Haematologica. doi: 10.3324/haematol.2018.206912
  • S.G.R. Verelst, H.M. Blommestein, S. de Groot, S. Gonzalez-McQuire, L. DeCosta, J.B. de Raad, C.A. de Uyl-de Groot & P. Sonneveld (2018). Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). HemaSphere, 2 (4). doi: 10.1097/HS9.0000000000000045
  • W.F. Thielen, H.M. Blommestein, L.E.M. Oosten, F.G. Calkoen, A.C. Lankester, J. Zwaginga, K. Le Blanc, A. Redondo, F. Sánchez‐Guijo, M. Algeri, F. Locatelli, W.E. Fibbe & C.A. Uyl - de Groot (2018). Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells: A decision model. European Journal of Haematology, 101 (5), 676-683. doi: 10.1111/ejh.13158 [go to publisher's site]
  • N. Büyükkaramikli, H.M. Blommestein, R. Riemsma, N. Armstrong, F.J. Clay, J. Ross, G. Worthy, J.L. Severens, J. Kleijnen & M.J. Al (2017). Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics (Print).
  • H.Y. Tan, M.G. Franken, H.M. Blommestein, C.A. Uyl - de Groot & P. Sonneveld (2017). Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. Journal of Clinical Oncology, 35 (12), 1312-+. doi: 10.1200/jco.2016.71.1663
  • S. de Groot, H.M. Blommestein, W.K. Redekop, S. Sleijfer, L. Kiemeney, E. Oosterwijk & C.A. de Uyl-de Groot (2017). Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. PLoS One (print), 12 (5):e0177364. doi: 10.1371/journal.pone.0177364
  • H.M. Blommestein, C.A. de Uyl-de Groot & S. Zweegman (2017). De econoom en de hematoloog: kosten, effecten en verantwoorde toegang tot zorg. Nederlands Tijdschrift voor Hematologie, 14 (6), 273-281.
  • C.H.Y. van Beurden-Tan, M.G. Franken, H.M. Blommestein, C.A. de Uyl-de Groot & P. Sonneveld (2017). Reply to X. Armoiry et al. Journal of Clinical Oncology, 35 (25), 2976. doi: 10.1200/JCO.2017.73.7569
  • J. Mihajlović, P. Bax, E. van Breugel, H.M. Blommestein, M. Hoogendoorn, W. Hospes & M.J. Postma (2017). Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion. Clinical Therapeutics, 39 (6), 1221-1232. doi: 10.1016/j.clinthera.2017.05.342
  • C.H.Y. van Beurden-Tan, M.G. Franken, H.M. Blommestein, C. Uyl-de Groot & P. Sonneveld (2017). Untitled Reply. Journal of Clinical Oncology, 35 (25), 2976-+. doi: 10.1200/jco.2017.73.7569
  • H.M. Blommestein, S. de Groot, M. Aarts, P. Vemer, R. de Vries, A.F.M. Abeelen, E.F.M. Posthuma & C.A. de Uyl-de Groot (2016). Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. Leukemia Research, 50, 37-45. doi: 10.1016/j.leukres.2016.09.005
  • H.M. Blommestein, P.C. Huijgens & C.A. de Uyl-de Groot (2016). De toegevoegde waarde van gegevens uit de dagelijkse praktijk. Nederlands Tijdschrift voor Hematologie, 13 (5), 206-208.
  • S. de Groot, N. van der Linden, M.G. Franken, H.M. Blommestein, B. Leeneman, E.M. van Rooijen, J.J.M. van der Hoeven, M. Wouters, H.M. Westgeest & C.A. de Uyl-de Groot (2016). Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences. Value in Health. doi: 10.1016/j.jval.2016.02.007
  • H.M. Blommestein, N. Armstrong, S. Ryder, S. Deshpande, G. Worthy, C. Noake, R. Riemsma, J. Kleijnen, J.L. Severens & M.J. Al (2016). Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. Pharmacoeconomics (Online), 34 (1), 23-31. doi: 10.1007/s40273-015-0318-3
  • W.F. Thielen, H.M. Blommestein & C.A. de Uyl-de Groot (2016). Using appropriate methods in cost-effectiveness analyses: the case of allogeneic hematopoietic cell transplantation in sickle cell disease. Biology of Blood and Marrow Transplantation, 22 (11), 2109-2110. doi: 10.1016/j.bbmt.2016.08.022
  • H.M. Blommestein, S.G.R. Verelst, S. de Groot, P.C. Huijgens, P. Sonneveld & C.A. de Uyl-de Groot (2015). A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. European Journal of Haematology, 96 (2), 198-208. doi: 10.1111/ejh.12571
  • H.M. Blommestein, M.G. Franken & C.A. de Uyl-de Groot (2015). A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry. Pharmacoeconomics (Print). doi: 10.1007/s40273-015-0260-4
  • H.M. Blommestein, M.G. Franken, S.G.R. Verelst, M. van Agthoven, P.C. Huijgens & C.A. de Uyl-de Groot (2014). Access to expensive cancer drugs in Dutch daily practice: Should we be concerned? Netherlands Journal of Medicine, 72 (4), 235-241. [go to publisher's site]
  • H.M. Blommestein, D. Issa, M. Pompen, G. Ten Hoor, M. Hogendoorn, P. Joosten, S. Zweegman, P.C. Huijgens & C.A. de Uyl-de Groot (2014). Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study. European Journal of Haematology, 92, 398-406. doi: 10.1111/ejh.12264
  • M.G. Franken, J.G. Gaultney, H.M. Blommestein, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2014). Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Value in Health, 17, 245-253. doi: 10.1016/j.jval.2013.12.009
  • A. Leunis, H.M. Blommestein, P.C. Huijgens, N.M.A. Blijlevens, M. Jongen-Lavrencic & C.A. de Uyl-de Groot (2013). The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leukemia Research, 37, 245-250. doi: 10.1016/j.leukres.2012.09.018
  • H.M. Blommestein, S.G.R. Verelst, P.C. Huijgens, N.M.A. Blijlevens, J.J. Cornelissen & C.A. de Uyl-de Groot (2012). Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Annals of Hematology, 91 (12), 1945-1952. doi: 10.1007/s00277-012-1530-2
  • H.M. Blommestein, S.G.R. Verelst, P.C. Huijgens, N.M.A. Blijlevens, J.J. Cornelissen & C.A. de Uyl-de Groot (2012). Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Annals of Hematology, 91, 1945-1952. doi: 10.1007/s00277-012-1530-2

• Report (1)

  • M.G. Franken, J.G. Gaultney, H.M. Blommestein, S.S. Tan, C.W.M. van Gils, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2012). Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma. (Extern rapport). Rotterdam: Erasmus Universiteit Rotterdam - GE-iMTA [go to publisher's site]

• Doctoral thesis (1)

  • H.M. Blommestein (2016, april 1). The added value of real-world evidence. EUR (203 pag.) (Rotterdam: Optima grafische commuicatie) Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & P.C. Huijgens.

Teaching (11)

Present position